Anti-CD22 antibody–drug conjugate that delivers calicheamicin to induce DNA double-strand breaks in CD22+ cells.
Humanized anti-CD22 IgG4 antibody-drug conjugate; after binding CD22 on B cells it is internalized and releases a calicheamicin derivative that binds the DNA minor groove, causing double-strand breaks and apoptosis.
YES
DIRECT
The ADC binds CD22, is internalized, and releases calicheamicin that induces DNA double-strand breaks, triggering apoptosis in CD22+ cells.
Anti-CD22 antibody–drug conjugate that delivers calicheamicin to induce DNA double-strand breaks in CD22+ cells.
Humanized anti-CD22 IgG4 antibody-drug conjugate; after binding CD22 on B cells it is internalized and releases a calicheamicin derivative that binds the DNA minor groove, causing double-strand breaks and apoptosis.
NO
INDIRECT
The ADC binds CD22 (not DNA) on B cells, is internalized, then releases calicheamicin that binds the DNA minor groove to cause double-strand breaks and apoptosis; DNA minor groove is the payload’s intracellular site, not the targeting antigen.
A nonreplicating modified vaccinia Ankara (MVA) recombinant viral-vector vaccine expressing CMV antigens IE1, IE2, and pp65; administered as two intramuscular doses (5.0 x 10^8 pfu) to elicit CMV-specific cellular immunity (CD8+ CTLs and CD4+ Th1) for prevention of primary CMV after D+R− liver transplant.
Nonreplicating MVA viral-vector vaccine that expresses CMV antigens IE1, IE2, and pp65 in host cells, leading to antigen presentation via MHC I/II by dendritic cells and induction of CMV-specific cellular immunity (CD8+ cytotoxic T cells and CD4+ Th1 responses) to prevent primary CMV infection post–liver transplant.
YES
INDIRECT
The vaccine primes CMV-specific CD8+ T cells that recognize IE1-derived peptides on MHC I of infected cells and kill them via perforin/granzyme-mediated cytotoxicity (with CD4+ Th1 support).
A nonreplicating modified vaccinia Ankara (MVA) recombinant viral-vector vaccine expressing CMV antigens IE1, IE2, and pp65; administered as two intramuscular doses (5.0 x 10^8 pfu) to elicit CMV-specific cellular immunity (CD8+ CTLs and CD4+ Th1) for prevention of primary CMV after D+R− liver transplant.
Nonreplicating MVA viral-vector vaccine that expresses CMV antigens IE1, IE2, and pp65 in host cells, leading to antigen presentation via MHC I/II by dendritic cells and induction of CMV-specific cellular immunity (CD8+ cytotoxic T cells and CD4+ Th1 responses) to prevent primary CMV infection post–liver transplant.
YES
INDIRECT
The vaccine induces IE2-specific CD8+ T cells; CMV-infected cells presenting IE2 peptides on MHC I are recognized and killed by CTLs via perforin/granzyme (and Fas–FasL) pathways.